Sun Pharma Funds New Dermatology Professorship in NYC
The endowment will support academic leadership and research at the Icahn School of Medicine at Mount Sinai.
Updated on Oct. 24, 2026 in Healthcare
Live Poll
Do you trust that corporate-funded professorships prioritize patient care over the interests of the donor?
Sun Pharma has established a $2.5 million professorship in dermatology at the Icahn School of Medicine at Mount Sinai in New York City. Dr. Mark G. Lebwohl has been named the inaugural professor to lead the department's academic efforts.
Why it matters
This endowed position aims to foster scientific innovation and train the next generation of leaders in dermatology. The funding bridges the gap between academic research and clinical application for skin-related treatments.
Sun Pharma, the second-largest dermatology pharmaceutical company in the U.S. by prescription volume, has committed $2.5 million to the new academic chair. The company currently supplies medicines to 100 countries globally.
The players
Sun Pharma
Headquartered in India, this pharmaceutical company is the second-largest provider of dermatology medications in the United States by prescription volume.
Icahn School of Medicine at Mount Sinai
Located in New York City, this institution is a leader in medical education and research.
Mark G. Lebwohl
He is the Dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai and the inaugural holder of the new professorship.
The details
The professorship is housed within the Kimberly and Eric J. Waldman Department of Dermatology at the medical school. Dr. Mark G. Lebwohl, who also serves as the Dean for Clinical Therapeutics, will utilize the endowment to advance scientific translation into clinical practice.
Timeline
October 24, 2026: The professorship establishment was reported.
2015 to 2016: Dr. Mark G. Lebwohl served as President of the American Academy of Dermatology.
Market Landscape
This partnership mirrors a trend where major pharmaceutical firms solidify influence by funding key academic chairs within top-tier medical departments. Such investments position these companies as essential partners to the institutions that drive future dermatological research and standard-of-care practices.
While the endowment does not directly change current drug pricing or retail availability, it strengthens the medical infrastructure available to local patients. Residents in New York City may benefit from accelerated research outcomes and advanced treatment protocols developed through this academic department.
The takeaway
The creation of this professorship signals a long-term commitment to dermatological advancement at a major teaching hospital. Students and patients benefit when pharmaceutical industry resources are successfully paired with academic expertise to solve complex skin conditions.
Further reading
Learn more about local medical developments in the Healthcare section.
Source note: This article includes information reported by Themachinemaker.
Live Poll
Do you trust that corporate-funded professorships prioritize patient care over the interests of the donor?
